Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
NKTR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $1.93
Previous CloseN/A
Volume706.47K
Average Volume (3M)2.10M
Market Cap
$149.18M
Enterprise Value$233.62M
Total Cash (Recent Filing)$194.91M
Total Debt (Recent Filing)$246.95M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
May 08, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding186,103,590
10 Day Avg. Volume1,463,627
30 Day Avg. Volume2,102,462
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.63
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.37
Enterprise Value/Ebitda-1.70
Forecast
1Y Price Target
$4.75Price Target Upside493.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Nektar Therapeutics News
PremiumCompany Announcements
Nektar Therapeutics’ Earnings Call: Optimism Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Commercial PotentialRezpeg could hold significant commercial potential due to its differentiated mechanism of action.
Development ProgressExpected timing for the Phase IIb trial results of rezpegaldesleukin in alopecia areata refined to the fourth quarter, showing progress in the development timeline.
Financial StabilityNKTR ended FY24 with $269.1M in cash and equivalents which the company is guiding as sufficient to fund operations into 4Q26.
Bears Say
Clinical RisksSome concerns have emerged re: placebo responses following these results that can likely be explained by high US recruitment and less severe patients.
Competitive RisksRisks include clinical, regulatory, commercial, competition, and dilution.
Financial PerformanceThe company reported a net loss of $31.8 million, which was better than the estimated net loss but worse than Street consensus.
---
Ownership Overview
11.05% Insiders
17.41% Mutual Funds
34.16% Other Institutional Investors
27.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $0.65 and its highest was $1.93 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $149.18M.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Mar 12, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.166.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 186,103,590 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in NKTR
---
Nektar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.75 (493.75% Upside)
$4.75 (493.75% Upside)
Blogger Sentiment
Bullish
NKTR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $48.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.00%
12-Months-Change
Fundamentals
Return on Equity
-124.10%
Trailing 12-Months
Asset Growth
-23.66%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
---
NKTR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials, financial stability, and strategic partnerships, particularly in autoimmune and inflammatory disease areas. However, challenges remain with potential placebo effects in trials and limited revenue growth in the near term. Overall, the call reflects a cautiously optimistic outlook with a balance of strategic achievements and ongoing challenges.Read More>---
NKTR Stock 12 Month Forecast
Average Price Target
$4.75
▲(493.75% Upside)
Technical Analysis
Best Analysts Covering NKTR
1 Year
1 Year Success Rate
12/17 ratings generated profit
1 Year Average Return
+52.05%
reiterated a sell rating last month
Copying Jessica Fye's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +52.05% per trade.
---